Company news
Starpharma Holdings Limited news in 2023
Starpharma Holdings Limited's news releases, calls and decks from 2023, newest first.
Positive DEP docetaxel Phase 2 results
December 18, 2023
AGM Chairman's address and CEO presentation
November 29, 2023
Starpharma announces new CEO, Ms Cheryl Maley
November 9, 2023
Starpharma receives $7.2 million R&D Tax Incentive refund
October 22, 2023
Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer
October 17, 2023
DEP irinotecan clinical data presented at AACR meeting
October 15, 2023
DEP irinotecan combination data presentation
September 26, 2023
VIRALEZ UK COVID-19 Clinical Study Completes Recruitment
September 25, 2023
Positive DEP irinotecan clinical results presentation
September 13, 2023
App 4E/Annual Report to shareholders
August 23, 2023
SPL to receive $6.5M from Mundipharma and VivaGel BV rights
August 13, 2023
Partnered Program Update
July 31, 2023
Trading Halt
July 28, 2023
Pause in Trading
July 28, 2023
Starpharma partners with UQ to advance DEP radio pipeline
July 25, 2023
DEP HER2-radiodiagnostic shows imaging benefits
July 20, 2023
Clinical Trial Update
June 27, 2023
Starpharma CEO to retire in 2024
June 8, 2023
VIRALEZE Nasal Spray Approved in Malaysia
June 5, 2023
HER2-targeted DEP SN38 ADC outperforms in HER2 cancer model
April 26, 2023
Interim Report and Half-Year Financial Results
February 27, 2023
Quarterly Activities Report & Appendix 4C
January 29, 2023
Response to ASX Query Letters
January 12, 2023
Decks in 2023
- Shareholder Meeting (November 2023)
Shareholder meeting · 48 slides · Nov 29, 2023
- OTCQX Virtual Life Sciences Investor Forum 2023
Conference · 42 slides · Jun 23, 2023